4834-98-4

Basic information

• Product Name: DODECANEDIOYL DICHLORIDE
• Synonyms: DODECANEDIOYL DICHLORIDE;1,10-Decanedicarboxylic acid dichloride;Dodecanedioic acid dichloride;Dodecanedioyl dichloride,98%;Dodecanedioyl dichloride, 98% 5GR;Dodecanedioyl dichloride 98%
• CAS NO: 4834-98-4
• Molecular Formula: C₁₂H₂₀Cl₂O₂
• Molecular Weight: 267.19
• Product Categories: Carboxylic Acid Monomers;Monomers;Polymer Science
• Mol File: 4834-98-4.mol
• Article Data: 37

Chemical Properties

• Boiling Point: 140 °C0.5 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: Clear yellow to brown/Liquid
• Density: 1.069 g/mL at 25 °C(lit.)
• Vapor Pressure: <0.75 mm Hg ( 20 °C)
• Refractive Index: n20/D 1.468(lit.)
• CAS DataBase Reference: DODECANEDIOYL DICHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: DODECANEDIOYL DICHLORIDE(4834-98-4)
• EPA Substance Registry System: DODECANEDIOYL DICHLORIDE(4834-98-4)

Safety Data

• Hazard Codes: C
• Statements: 34-36/37
• Safety Statements: 26-27-28-36/37/39-45
• RIDADR: UN 3265 8/PG 2
• WGK Germany: 3
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 4834-98-4(Hazardous Substances Data)

Usage

Chemical Properties

clear yellow to brown liquid

InChI:InChI=1/C12H20Cl2O2/c13-11(15)9-7-5-3-1-2-4-6-8-10-12(14)16/h1-10H2

Upstream product

• 821-38-5 1,14-tetradecanedioic acid 
• 693-23-2 1,12-dodecanedioic acid 

Downstream Products

• 63240-97-1 <10,10>betweenanene 
• 63240-97-1 Dicyclo<10.10.0>docos-1(12)-en 
• 202590-86-1 N,N'-bis[4-[2-(dibutylamino)-1-(2-hydroxybenzoyloxy)ethyl]quinolin-8-yl]dodecanediamide 
• 50905-01-6 N,N'-Dicyclohexyl-1,10-dicarbamoyldecan 
• 71857-84-6 C₄₈H₆₀N₆O₁₀ 
• 98259-17-7 N₁,N₁₂-diphenyldodecanediamide 
• 38300-52-6 cyclodocosane-1,12-dione 

Relevant articles and documents

Synthesis of new, pyrene-containing, metal-chelating lipids and sensing of cupric ions

(Matrix presented) The syntheses of several saturated, pyrene-containing, metal-chelating lipids are described. These lipids are capable of strongly binding to transition metal ions employing the metal-chelating headgroup. The excimer-to-monomer ratio of

LIPID PRODRUGS OF NEUROSTEROIDS

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

LIPID PRODRUGS OF BTK INHIBITORS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.